BOT 5.26% 36.0¢ botanix pharmaceuticals ltd

FDA approves Winlevi, page-16

  1. 2,763 Posts.
    lightbulb Created with Sketch. 590
    IMO we are at the point where BTX 1503 is effectively at Phase 3 and there is a 2/3 chance of advancing to FDA approval.

    ... which would suggest that the company is a tad undervalued.


 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.